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Abstract
Background: Patented crystalline glucosamine sulfate (pCGS) and diacerein monotherapy have been recommended
for treatment of mild to moderate osteoarthritis (OA), but evidence of efficacy for combined treatments is lacking.
Therefore, the aim of this study was to compare clinical outcomes (i.e., pain and Western Ontario and McMaster
Universities Osteoarthritis Index [WOMAC] score) at 6 months as well as the safety profile of treatment with
combined pCGS and diacerein versus pCGS alone.
Methods: A double-blind, parallel randomized controlled superiority trial was conducted between August 2013
and August 2014 at Ramathibodi Hospital, Bangkok, Thailand. A total of 148 patients (74 patients in each group)
was randomly allocated to receive pCGS plus diacerein or pCGS plus placebo daily. Adult patients with OA were
eligible if they had a Kellgren-Lawrence grade of 2–3. The primary outcomes were visual analogue scale score
(VAS) for pain and WOMAC subscores measured at 24 weeks after receiving treatment, using the intention-to-treat
principle (nonresponder imputation).
Results: Among the 148 patients in the study, mean age and body mass index were 60 years and 28.1 kg/m2,
respectively. Mean VAS and minimal joint space width at baseline were 5.1 and 2.5 mm, respectively. The mean
VAS values measured at 24 weeks were 2.97 and 2.88 in the pCGS plus diacerein and pCGS plus placebo groups,
respectively. The estimated mean difference was 0.09 (95 % CI −0.75 to 0.94), which was not statistically significant
(P = 0.710). In addition, the mean WOMAC total, pain, function, and stiffness scores for both groups were not
significantly different, with corresponding means of 48.59, 12.02, 32.74, and 3.85 for the pCGS plus diacerein
group and 48.69, 11.76, 32.47, and 4.16 for the pCGS plus placebo group. The risk of diarrhea and dyspepsia was
very similar between the two groups, with risk ratios of 1.03 (95 % CI 0.56–1.89) and 0.91 (95 % CI 0.43–1.92),
respectively.
Conclusions: This study did not demonstrate that coadministration of diacerein with pCGS improves pain and
WOMAC score compared with pCGS monotherapy in patients with mild to moderate OA of the knee.
Trial registration: ClinicalTrials.gov identifier: NCT01906801. Registered on 20 July 2013.
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Background
Osteoarthritis (OA), a degenerative joint disease, is the
most common health problem in the United States [1].
According to the Global Burden of Disease 2013 project,
musculoskeletal disorder contributes 6.8 % of the total
disability-adjusted life-years(DALYs), with 10 % of this due
to OA [2]. Increased longevity and obesity in most devel-
oped countries are expected to dramatically increase the in-
cidence and prevalence of OA of the knee within the next
decade [1, 3]. Current estimates indicate that the prevalence
rates of knee OA are approximately 15 % in the United
States [4] and about 34.5–45.6 % in elderly Thai [5]. It has
been estimated that 40 % of the population aged over
65 years is affected by knee or hip symptomatic OA [6, 7].
Currently, there is no known cure for OA, and no
intervention has been unequivocally demonstrated to
delay disease progression before joint replacement surgery
[8]. As for pharmacologic therapy, first-line drugs for OA
are used purely for managing pain. Analgesic agents and
nonsteroidal anti-inflammatory drugs (NSAIDs), including
cyclooxygenase 2 inhibitors, are the most widely pre-
scribed. However, the side effects of these treatments,
which include an increased risk of cardiovascular events
(e.g., heart attacks and stroke [9]), suggest that these drugs
should be used with caution and should be avoided in
patients with OA who have underlying cardiovascular
disease [10]. Therefore, there remains a need for a
therapeutic agent for OA that has symptom-modifying
effects, a better safety profile, and positive (or at least
no negative) effects on cartilage [11].
Patented crystalline glucosamine sulfate (pCGS) and
diacerein are commonly used for treatment of symptom-
atic mild to moderate knee OA to relieve joint pain and
delay joint destruction and cartilage loss. pCGS was de-
veloped as a prescription drug for OA in Europe and
Asia, but it is available as an over-the-counter product
in the United States and Australia. Diacerein is also
available as an over-the-counter product in some coun-
tries in Asia, but not in other countries (e.g., Thailand)
[8]. pCGS is found naturally in the human body, acting
as one of the building blocks of cartilage and a precursor
for glycosaminoglycan, a major component of joint car-
tilage [12]. Diacerein works by inhibiting interleukin-1,
one of the first cytokines that induces fever, controls
lymphocytes, increases the number of bone marrow
cells, and causes degeneration of the bone joint [13].
The efficacy of pCGS and diacerein compared with
placebo and active drugs has been estimated in system-
atic reviews and a network meta-analysis of randomized
controlled trials (RCTs) [14–17]. The results of these
investigations suggest that diacerein may be better than
glucosamine for reducing pain, but both have similar
efficacy for improving joint function. Because pCGS and
diacerein have anabolic [18, 19] and catabolic effects [13],
respectively, combining them may have synergetic effects
and thus improve pain and function better than monother-
apy. However, no RCT has directly compared the clinical
outcomes between monotherapy (i.e., diacerein or pCGS)
and a combination of the two drugs. We thus wanted to
determine whether combined diacerein and pCGS is super-
ior to pCGS alone. Therefore, we conducted a RCT with
the aim of comparing clinical outcomes (i.e., pain and OA
score) at 6 months as well as the safety profiles of treatment
with combined pCGS and diacerein versus pCGS alone.
Methods
Trial design
The study design was a double-blind, parallel, randomized,
controlled superiority trial. The trial was conducted at the
orthopedics outpatient clinic of Ramathibodi Hospital,
Bangkok, Thailand, between August 2013 and August
2014. It was conducted according to the original protocol
regarding trial design, treatments, and outcome assess-
ments, except dealing with missing data using imputation.
The trial was also conducted and reported in accordance
with the Consolidated Standards of Reporting Trials
(CONSORT) statement.
Eligibility criteria
Patients were recruited from the orthopedic outpatient
clinic at Ramathibodi Hospital by orthopedic residents and
staff between August 2013 and August 2014. Residents
and staff were trained in how to recruit and inform
patients about the trial. Patients were eligible if they
met all of the following criteria:
 Diagnosed as having primary or secondary knee
OA based on the clinical criteria of the American
College of Rheumatology [20] (i.e., knee pain
measured with a visual analogue scale [VAS] plus
three of the following: aged 50 years or older, bony
tenderness, stiffness lasting less than 30 minutes,
bony enlargement, crepitus, or warm to touch)
 Had not received pCGS or diacerein within
previous 6 months
 Had radiographic evidence of OA with a Kellgren-
Lawrence grade of 2 or 3
 Were willing to participate and provided consent
Patients were excluded if they had any of the following:
 Had undergone knee replacement surgery
 Inflammatory arthritis (e.g., systemic lupus
erythematosus, rheumatoid arthritis, gout) and
posttraumatic arthritis
 Previous intra-articular treatment of the knee joint
with any product (corticosteroids in the previous
2 months or hyaluronic acid in the previous 6 months)
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 Gastrointestinal conditions (gastroesophageal reflux
disorder, inflammatory bowel syndrome, peptic
ulcer, and duodenal ulcer), renal disease, liver
disease, or diabetes mellitus
Treatment regimen and randomization
Eligible patients were randomly assigned to receive ei-
ther a sachet of pCGS 1500 mg (Rottapharm Madaus,
Monza, Italy) plus placebo once daily or pCGS 1500 mg
plus diacerein 50 mg once daily (TRB Chemedica Inter-
national S.A., Geneva, Switzerland) for 6 months. TRB
Chemedica International prepared placebo capsules
identically to diacerein by appearance, smell, and taste.
Patients, physicians, assessors, and research nurses did
not know which one was the active drug or the placebo.
A block randomization with a ratio of 1:1 was applied
to generate a randomization list, with varying block sizes
of 4–8. This procedure was prepared by a biostatistician
(AT) who was not involved in patient recruitment or
data collection. STATA version 13.0 software (StataCorp,
College Station, TX, USA) was used to generate the ran-
dom sequence lists [21], which were then prepared using
coded drug packages and administered by a research
nurse if patients met the inclusion criteria and had given
informed consent. Patients might be prescribed other
pain relief (acetaminophen 500 mg or NSAIDs), depend-
ing on the physician’s judgment. The use of NSAIDs
could be started with ibuprofen 400 mg one tablet three
times per day or naproxen 250 mg one tablet two times
per day if patients were allergic to ibuprofen. The pa-
tients were provided with a diary to record their daily
pain medication intake.
Outcome measures
The primary outcomes of interest were pain score mea-
sured at 24 weeks using a VAS (ranging from 0 to 10,
where higher score indicates greater pain) and the OA
score measured at 24 weeks using the Thai version of
the Western Ontario and McMaster Osteoarthritis Index
(WOMAC) [22]. The WOMAC consists of 3 domains
and 22 items comprising pain (5 items), function (15
items), and stiffness (2 items). Each item was graded
from 0 to 10, with higher scores indicating more severe
symptoms. Total and subdomain scores were calculated
by summation of scores for relevant items. The total
scores range from 0 to 220, where higher scores indicate
more severe OA.
The secondary outcomes of interests were WOMAC
subscores for pain, function, stiffness, and joint space
width (JSW). The WOMAC scores were measured by a
well-trained research assistant using WOMAC question-
naires at baseline and weeks 4, 8, 12, 16, 20, and 24 after
treatment. JSW was assessed using weight-bearing meta-
tarsophalangeal radiography at baseline, 12 weeks, and
24 weeks, and determined by computer-generated mea-
surements taken from digitized images. JSW was defined
as the distance from the distal femoral condyle to the
proximal tibia, and it was measured by one orthopedist
(JK) at 12 and 24 weeks after treatment. The intra- and
interobserver reproducibility of this technique were con-
sidered to be acceptable, with an interobserver intraclass
coefficient of correlation of 0.912 (0.887–0.931) and an
intraobserver intraclass coefficient of correlation of
0.996 (0.991–0.998) [23]. In addition, adverse events,
including gastrointestinal effects (i.e., dyspepsia and
diarrhea), were assessed at each visit after treatment. All
adverse events reported by the patients during the study
treatment were recorded on their Case Report Form and
classified in terms of type, time of onset, severity (mild,
moderate, or severe), duration, and outcome. The phys-
ician asked the patient, “How well did you tolerate the
test medication?” and recorded the patient’s response.
All the information concerning expected adverse events
was provided on the informed consent form. Informa-
tion regarding other covariables, including age, sex, knee
symptoms (i.e., warmth and stiffness), underlying disease
(i.e., diabetes, hypertension, malnutrition, cardiovascular
disease, and obesity as defined by body mass index
[BMI] ≥30 mg/m2), and disease severity at baseline, was
also collected.
Statistical analysis
The sample size was calculated on the basis of a super-
iority trial detecting a mean difference in VAS between
pCGS plus diacerein and pCGS plus placebo. For the
meta-analysis [24], the mean and SD of VAS scores in
the pCGS group were 4.78 and 1.9, respectively. Type I
error with a two-sided test, power of test, and ratio of
the treatment groups were set at 0.05, 0.80, and 1:1, re-
spectively. The estimated sample size needed was 59 for
each group to detect a mean difference in VAS score of
1 unit. Loss to follow-up was estimated at 20 %, which
yielded a required sample size of 148 patients.
Data were described using frequency for categorical
data and mean (SD) or median (range) where appro-
priate for continuous data. The distributions of these
baseline characteristics were then explored. If the dis-
tributions were different between the two intervention
groups (i.e., ≥10 % for binary/categorical variables and ≥1
of the pooled SD for continuous variables), these variables
were then considered for adjustment in the main analysis.
Continuous data for both primary and secondary out-
comes, including VAS pain score and WOMAC total
scores and subscores at 24 weeks, were compared be-
tween treatment groups using a mixed linear regression
analysis with a hierarchical approach, in which a subject
variation term was fitted in the model as a random effect
and treatment was considered as a fixed effect. Marginal
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treatment effects between treatments and times were
then estimated and compared. Covariables at baseline
were included if they were unequally distributed between
two groups as mentioned above. The normality of re-
siduals of the mixed model was then checked using
normality plots (i.e., quantile of normal distribution)
and the Shapiro-Wilk test. Diagnostic measures were
explored if the assumption of normality was violated.
The continuous outcomes were then transformed
where appropriate to meet the assumption.
Secondary outcomes with dichotomous data (i.e., ad-
verse events at 24 weeks) were compared between treat-
ment groups using a mixed-effects Poisson regression
analysis in which a subject variation was fitted in the
model as a random effect and the treatment was consid-
ered as a fixed effect. The incidence of adverse events in
both groups and a ratio of the incidence (i.e., a risk ratio
[RR]) between treatments and times were then estimated
and compared. Unbalanced covariables at baseline were
also included in a Poisson regression model.
An intention-to-treat (ITT) approach was applied for
all analyses if there was any evidence of a protocol viola-
tion. Missing outcome data were imputed for maintain-
ing ITT using a multivariate normal regression analysis
with 20 replications [25]. Complete data (i.e., age, sex,
BMI, VAS, and WOMAC subdomain scores at baseline)
were used to simultaneously predict VAS and WOMAC
subdomain scores after treatments. All analyses were
performed using STATA version 14.0 software [21]. The
Bonferroni correction was applied to adjust for inflation
of type I error from six outcomes and thus six multiple
tests [26]. If a significance level for the whole family of
tests was 0.05, then the Bonferroni-corrected threshold
for individual tests was 0.0083.
Results
Patient characteristics
A total of 148 patients was recruited and randomly allo-
cated to treatment groups (see Fig. 1). Of these, 1 patient
was ineligible because his pain scores on the VAS and
WOMAC at baseline were 0, leaving 147 patients for as-
sessment of clinical outcomes. Baseline characteristics
were described, and their distributions between treat-
ment groups were explored (see Table 1). In the pCGS
plus diacerein group, the majority were female (83.1 %),
the mean (±SD) age was 58.8 (±6.6) years, and the mean
BMI was 28.9 (±5.3) kg/m2. The mean age in the pCGS
plus placebo group was about 2.4 years older, and the
mean BMI was about 1.7 kg/m2 lower, than in the pCGS
plus diacerin group. The rest of the variables and disease
severity at baseline, including pain, function, and stiff-
ness scores were comparable between treatment groups.
Thirteen patients in the pCGS plus placebo group had
diabetes, as did eight patients in the pCGS plus diacerein
group; there were no differences between treatment
groups. The number of remaining pills and painkillers
used, including NSAIDs and paracetamol, were recorded
at every visit; there were no differences in rescue pain
medication between treatment groups.
Patient compliance with the allocated treatments,
measured by counting the number of capsules at each
visit, ranged from 88 % to 100 % in the pCGS plus dia-
cerein group and from 79 % to 100 % in the pCGS plus
placebo group. A total of 18 participants (9 per group)
did not finish the study at 6 months. When we com-
pared this group with the 130 participants (65 per
group) who finished the study at 6 months, we observed
no differences in baseline characteristics (see Additional
file 1: Table S1). Loss to follow-up in these two corre-
sponding groups ranged from 1.4 % to 12.2 %. These
outcome data of 46 patients were then imputed using
complete baseline data with 20 replications. These im-
puted and complete outcome data of 147 patients were
used for further analyses using the ITT approach.
VAS pain score
Applying a mixed-effects regression model with adjust-
ments for age and BMI yielded mean VAS scores at
24 weeks of 2.97 (95 % CI 2.38–3.56) and 2.88 (95 % CI
2.29–3.47) in the pCGS plus diacerein and glucosamine
plus placebo groups, respectively (see Table 2). This indi-
cated no significant difference between the two groups,
with an estimated mean difference of 0.09 (95 % CI −0.75
to 0.94).
The mean VAS scores were plotted by treatment
and time, which indicated declining VAS scores after
treatment in both groups (see Fig. 2). The mean VAS
scores in the pCGS plus diacerein group at 1, 2, 3, 4,
5, and 6 months were 4.07, 3.58, 3.61, 3.36, 3.32, and
3.15, respectively; the corresponding values in the
pCGS and placebo group were 4.72, 4.19, 3.74, 3.47,
3.29, and 2.77.
Post hoc analysis was performed in a subgroup of
patients whose VAS pain scores at baseline were 5 or
higher. The overall mean VAS scores were 6.72 ± 1.69
and 6.92 ± 1.56 in the combined treatment and mono-
therapy groups, respectively, but there was no statisti-
cally significant difference (P = 0.607).
WOMAC total score
Applying the mixed-effects regression model with ad-
justments for age and BMI yielded mean WOMAC total
scores at 24 weeks of 48.59 (95 % CI 38.30–58.89) and
48.69 (95 % CI 38.34–59.05) in the pCGS plus diacerein
and glucosamine plus placebo groups, respectively (see
Table 2). This indicated no significant difference between
the two groups, with an estimated mean difference of −0.1
(95 % CI −14.95 to 14.75).
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Mean WOMAC total scores were plotted by treatment
and time, which indicated declining WOMAC scores in
both treatment groups (see Fig. 3a). The mixed-effects
regression model indicated no significant difference be-
tween the two groups at each distinct time point.
WOMAC pain score
Applying the mixed-effects regression model with ad-
justments for age and BMI yielded mean WOMAC pain
scores at 24 weeks of 12.02 (95 % CI 9.53–14.52) and
11.76 (95 % CI 9.25–14.27) in the pCGS plus diacerein
and glucosamine plus placebo groups, respectively (see
Table 2). This indicated no significant difference be-
tween the two groups, with an estimated mean differ-
ence of 0.26 (95 % CI −3.34 to 3.86). Mean WOMAC
pain scores were plotted by treatment and time, which
indicated declining WOMAC scores in both treatment
groups (see Fig. 3b).
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) 2010 flow diagram
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Table 1 Baseline characteristics of patients between treatment groups
Characteristics Glucosamine sulfate plus diacerein
(n = 74)
Glucosamine sulfate plus placebo
(n = 74)
Age, years, mean (SD) 58.8 (6.6) 61.2 (7.3)
Sex, %
Male 11 (14.9) 14 (18.9)
Female 63 (85.1) 60 (81.1)
BMI, kg/m2, mean (SD) 28.9 (5.3) 27.2 (4.2)
Knee symptoms, n (%)
Warmth
Yes 22 (30.14) 24 (32.43)
No 51 (69.86) 50 (67.57)
Stiffness
Yes 39 (52.7) 33 (44.6)
No 35 (47.3) 41 (55.4)
Duration of symptoms before enrollment, months, median (range) 12 (2–120) 12 (2–120)
Drug allergy, n (%)
Yes 15 (20.3) 15 (20.3)
No 59 (79.7) 59 (79.7)
Underlying disease, n (%)
Diabetes
Yes 8 (10.8) 13 (17.6)
No 65 (89.2) 61 (82.4)
Hypertension
Yes 40 (54.1) 34 (45.9)
No 34 (45.9) 40 (54.1)
Dyspepsia
Yes 8 (11.76) 7 (9.86)
No 60 (88.24) 64 (90.14)
Other disease
Yes 34 (45.9) 32 (43.2)
No 40 (54.1) 42 (56.8)
Defecation
Normal 59 (79.7) 54 (73)
Abnormal 15 (20.3) 20 (27)
Smoking
Yes 1 (1.4) 3 (4)
No 73 (98.6) 71 (96)
Alcohol drinking
Yes 7 (9.5) 3 (4)
No 67 (90.5) 71 (96)
Family history of OA knee
Yes 25 (33.8) 31 (41.9)
No 49 (66.2) 43 (58.1)
Quadriceps exercises
Yes 46 (62.2) 48 (64.9)
No 28 (37.8) 26 (35.1)
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WOMAC stiffness score
The mixed-effects regression model with adjustments
for age and BMI yielded mean WOMAC stiffness scores
at 24 weeks of 3.85 (95 % CI 2.79–4.91) and 4.16 (95 %
CI 3.07–5.26) in the pCGS plus diacerein and glucosa-
mine plus placebo groups, respectively (see Table 2).
This indicated no significant difference between the
two groups, with an estimated mean difference of −0.32
(95 % CI −1.87 to 1.24). Mean WOMAC stiffness scores
were plotted by treatment and time, which indicated
declining WOMAC scores in both treatment groups
(see Fig. 3c).
WOMAC function score
The mixed-effects regression model with adjustments
for age and BMI yielded mean WOMAC function scores
at 24 weeks of 32.74 (95 % CI 25.70–39.79) and 32.74
(95 % CI 25.66–39.82) in the pCGS plus diacerein and
glucosamine plus placebo groups, respectively (see Table 2).
This indicated no significant difference between the
two groups, with an estimated mean difference of 0.01
(95 % CI −10.15 to 10.16).
Mean WOMAC function scores decreased over time
for both treatments (see Fig. 3d). Applying the mixed-
effects regression model indicated no significant differ-
ence between the two groups at each distinct time point.
Minimal joint space width
Using an ITT analysis approach and applying the mixed-
effects regression model with adjustments for age and
BMI yielded mean JSWs at 24 weeks of 2.63 mm (95 % CI
2.41–2.84) and 2.59 mm (95 % CI 2.37–2.81) in the pCGS
plus diacerein and glucosamine plus placebo groups, re-
spectively (see Fig. 4). This indicated no significant dif-
ference between the two groups, with an estimated
mean difference of 0.04 mm (95 % CI −0.35 to 0.27).
Adverse events
The mixed-effects Poisson regression model was applied
to estimate the risk of occurrence of dyspepsia and diar-
rhea with adjustments for age and BMI. The estimated
risk of diarrhea after treatment was very close between
the two groups (0.084 [0.051–0.136] for pCGS plus dia-
cerein vs. 0.081 [0.048–0.138] for pCGS plus placebo)
with an RR of 1.026 (95 % CI 0.559–1.885) (see Table 3).
The risks of dyspepsia were also very similar (i.e., 0.030
[0.015, 0.059] vs 0.033 [0.017, 0.066]) with an RR of
0.910 (95 % CI 0.432–1.918).
Table 1 Baseline characteristics of patients between treatment groups (Continued)
Kellgren-Lawrence grade 2, % 81.1 76.4
VAS pain score, mean (SD) 5.01 (2.55) 5.05 (2.61)
WOMAC score
Total, mean (SD) 82.3 (47.3) 81.4 (44.1)
Pain, mean (SD) 21.3 (11.8) 21.1 (12.3)
Stiffness, median (range) 6.5 (0–20) 4.5 (0–20)
Function, mean (SD) 54.2 (32.7) 54.4 (29.3)
Joint space width, mm, mean (SD)
Medial minimal width, right 2.98 (0.82) 2.82 (0.84)
Lateral minimal width, right 4.25 (1.28) 4.32 (1.12)
Medial minimal width, left 2.83 (0.84) 2.90 (0.78)
Lateral minimal width, left 4.35 (1.10) 4.28 (1.15)
Abbreviations: BMI Body mass index, OA Osteoarthritis, VAS Visual analogue scale, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index





95 % CI P value
Glucosamine plus diacerein Glucosamine plus placebo
VAS score 2.97 (2.38–3.56) 2.88 (2.29–3.47) 0.09 −0.75, 0.94 0.710
WOMAC scores
Total 48.59 (38.30–58.89) 48.69 (38.34–59.05) −0.10 −14.95, 14.75 0.990
Pain 12.02 (9.53–14.52) 11.76 (9.25–14.27) 0.26 −3.34, 3.86 0.887
Stiffness 3.85 (2.79–4.91) 4.16 (3.07–5.26) −0.32 −1.87, 1.24 0.687
Function 32.74 (25.70–39.79) 32.74 (25.66–39.82) 0.01 −10.15, 10.16 0.999
JSW, mm 2.63 (2.41–2.84) 2.59 (2.37–2.81) 0.04 −0.35, 0.27 0.803
Abbreviations: JSW Joint space width, VAS Visual analogue scale, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index
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The most common adverse event was abnormal urine
(red or orange color), seen in 87.7 % of patients receiv-
ing pCGS plus diacerein and in 66.2 % of the patients re-
ceiving pCGS plus placebo. For approximately one-third
of the patients, the adverse events were related to the
gastrointestinal system (diarrhea, gastritis, constipation,
and nausea); however, there were no significant differ-
ences between groups in this regard. Approximately
10 % of patients in both groups reported skin reactions.
No adverse events led to the dropout of any patient or
Fig. 2 Mean visual analogue scale scores by treatment group and time
a b
c d
Fig. 3 Western Ontario and McMaster Universities Osteoarthritis Index mean total scores and subscores by treatment group and time
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discontinuation of any medication. No deaths occurred
in this study. Parameters determined on the basis of vital
signs and physical examinations were similar in both
groups. The consumption of rescue medication in this
study (i.e., other pain medication) was low and similar
between the two groups.
Discussion
We conducted a double-blind RCT to compare the effi-
cacy of the combination of pCGS plus diacerein with
pCGS plus placebo in the treatment of knee OA. Our
findings suggest that combined treatment does not re-
duce VAS pain score, WOMAC total score, or WOMAC
subscores compared with pCGS monotherapy in patients
with mild to moderate knee OA. Although the efficacy
in both treatment groups did not differ, clinical signs
and symptoms were improved in both treatment groups
at 12–24 weeks, and this was particularly evident in the
pCGS plus placebo group.
pCGS, which comprises essential components of the
proteoglycans in normal cartilage, is found naturally in
the knee joint of the human body. With its possible ana-
bolic effect, it is used for inhibition of metalloproteinase
activity, prostaglandin E2 release, nitric oxide produc-
tion, degradation of glycosaminoglycans, and stimulation
of the synthesis of hyaluronic acid in the joint [12, 27].
It has a slow onset of response, provides long-lasting
pain relief and functional improvement, and delays pro-
gression of the joint space [28, 29] in OA of the knee
[12, 30, 31]. Diacerein may be beneficial for OA in that
it inhibits interleukin-1, controls lymphocytes, increases
the number of bone marrow cells, and reduces degener-
ation of the bone joint [13]. As a result, diacerein is also
claimed to improve pain and function in OA of the knee
[30, 32–34]. In a recent animal study, researchers found
chondroprotective effects of diacerein and pCGS, but a
better range of motion of the knee joint was found in
response to diacerein than to pCGS [35]. With the
different mechanisms of action of pCGS and diacerein,
it could be expected that combined treatments should
result in synergetic effects.
Our findings are similar to those of a previous study
in which researchers compared combined pCGS plus
chondroitin sulfate with pCGS or chondroitin sulfate
alone in patients with OA of the knee whose Kellgren-
Lawrence grade was 2–3 [31]. That study was later
combined in a network meta-analysis [36], which
showed similar results. Although the potential synergis-
tic effects derived from a pharmacologic study of pCGS
and diacerein [27] looked promising, our findings indi-
cate that combined treatments did not provide any
benefit over monotherapy.
Fig. 4 Mean difference of joint space width between glucosamine plus diacerein and glucosamine groups at different time points
Table 3 Incidence and risk ratio of adverse events between the two treatment groups
Outcomes at
6-month follow-up
Treatment RR 95 % CI P value
Glucosamine plus diacerein Glucosamine plus placebo
Diarrhea 0.84 (0.05–0.14) 0.81 (0.05–0.14) 1.03 0.56–1.89 0.932
Dyspepsia 0.03 (0.02–0.06) 0.03 (0.02–0.07) 0.91 0.43–1.92 0.805
RR Risk ratio
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Strengths and limitations
To the best of our knowledge, this is the first double-
blind RCT designed to assess the effects of combined
pCGS plus diacerein versus pCGS monotherapy with
6 months of follow-up. The active treatments, both cap-
sules and sachets, were identical in appearance and were
administered to patients using coded drug packs; there-
fore, patients, investigators, and outcome assessors were
truly blinded. We considered the most relevant outcomes,
including subjective (i.e., VAS pain score, WOMAC total
score, and WOMAC subscores) and objective (i.e., min-
imal tibiofemoral JSW) measures. In addition, all possible
adverse effects were collected. Drug compliance was
reasonably high, ranging from 88 % to 100 % and 79 %
to 100 % in the combined treatment and monotherapy
groups, respectively (P = 0.133). Cointervention with
additional pain medications was also similar at 17.6 %
versus 21.6 % in the combined treatment and mono-
therapy groups, respectively (P = 0.534). We applied an
ITT analysis by considering all patients in the groups to
which they were originally randomly allocated, thus
minimizing bias.
Our study has some limitations. The dosage of diacerein
that we used was 50 mg in the combined treatment group
because the side effect of diacerein has been shown to
have a correlation to the drug dosage in prevention of
drug withdrawal, according to a previous study in which
researchers compared diacerein in different dosages (50,
100, and 150 mg) with placebo. The highest safety profile
is at a dose of 50 mg/day, and we did not up-titrate the
dose. However, the positive effects on VAS pain symptoms
are decreased in a dose-dependent manner as the dose is
decreased [34]. This could explain the lack of difference
between the two treatment groups.
The sample size calculation was computed to assess
primary outcomes between groups, but it may not be
generalized to assessment of secondary outcomes; there-
fore, statistical insignificance might be due to the risk of
type II errors. We considered mostly patients with knee
OA with mild to moderate pain scores at baseline, which
might have made it difficult to detect the benefits of
combined treatment. In addition, our patients with knee
OA were mainly diagnosed. The uncertain clinical diag-
nosis and classification may affect the outcomes of clinical
studies [37–41]. There is a widespread belief that there is
a high discordance between clinical and radiographic knee
OA. In an attempt to overcome this problem, we included
the participants in our study on the basis of American
College of Rheumatology criteria [20] for diagnosis of
knee OA with the radiographic criteria of Kellgren-
Lawrence grade 2–3 [42]. However, the Kellgren-
Lawrence classification strongly depends on adequate
patient positioning when taking x-rays. It is also not
specific to cartilage loss. Magnetic resonance imaging
(MRI) provides somewhat superior sensitivity to change
compared with commonly used radiographs, and it has
recently provided non-location-dependent measures of
cartilage thickness loss and gain, which are potentially
more sensitive in detecting symptomatic slow-acting
drug for osteoarthritis effects than radiographic JSW.
The cost of MRI is about 20 times greater than that of
radiographs; therefore, we used radiographically mea-
sured JSW with strict positioning to obtain the highest-
quality outcome measurements. Moreover, knee pain
and function of patients with these inclusion criteria,
which we assessed using subjective outcome VAS and
WOMAC scores, may be imprecise owing to the non-
specific nature of knee pain (e.g., non-OA pathology
such as tendinitis or muscle strain, referred pain, and
nonphysical pain such as depression), and all these fac-
tors can coexist at the same time, composing multiple
layers of causality of knee pain [37].
The potential sources of bias that could substantially
impact interpretation of the trial were noncompliance,
cointervention, and contamination. For cointervention
and contamination, there were no reports of use of non-
protocol medications or other cotreatments, which
meant cointervention or contamination between the
groups was unlikely. However, the data were analyzed by
the ITT method. As for compliance, missing outcome
data were imputed using a multivariate normal regression
analysis with 20 replications. Complete data (i.e., age, sex,
BMI, VAS and WOMAC subdomain scores at baseline)
were used to simultaneously predict VAS and WOMAC
subdomain scores after treatment.
We measured outcomes over 6 months owing to time
restrictions, making the study a short-term assessment.
However, according to previous studies of both drugs,
there have been long-term effects lasting up to about
1 year (longest effect lasted 3 years). There were also
sustained effects lasting longer than 3 months; therefore,
when assessing stratified patients with knee OA in a
subgroup with longer follow-up times, a sustained effect
could be considered to deduce the benefits of combined
treatment. Replication using larger samples with repeated
measurements might show greater, more conclusive dif-
ferences in all possible outcomes over time between the
two groups. This information could be used to more prop-
erly address the treatment effects. Moreover, the results
derived from this study were based on plain radiographs,
which may not be sufficient to assess knee cartilage, the
major component that responds to both drugs (based on
the JSW of the knee joint). MRI may better facilitate the
assessment of cartilage changes in the knee joint in the
next study because MRI is much more sensitive than plain
radiography. However, in this study, we assessed JSW at 3
and 6 months. These time periods may not be adequate
for assessing changes in JSW and may be a reason for the
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insignificant results regarding radiographic changes in
JSW. In postmarketing data, elevations in serum liver
enzymes and acute hepatic injury have been recorded.
In this study, although participants with preexisting
liver problems were excluded, there were no measures
to monitor liver toxicity; therefore, we were unable to
detect any potential liver-related adverse drug events.
Finally, there are various generic preparations of glu-
cosamine that were approximately five times cheaper
than the original ones. Bioequivalence trials between
original and generic glucosamine samples should be
conducted.
Conclusions
This study did not demonstrate that coadministration of
diacerein with pCGS improves pain and WOMAC scores
compared with pCGS monotherapy in patients with mild
to moderate OA with Kellgren-Lawrence grade 2–3. Both
combined therapy and monotherapy can significantly
reduce VAS pain and WOMAC function scores after
3–6 months compared with baseline.
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